LSJ Tamiflu 30mg and 75mg_Final_Redacted.pdf

This Limited Source Justification document from the Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response seeks to procure Tamiflu 30mg and 75mg capsules on a sole source basis from Roche Laboratories Inc. The department requires 500,000 treatment courses of Tamiflu capsules to maintain in the Strategic National Stockpile for potential pandemic influenza outbreaks or other public health emergencies. Roche Laboratories Inc. is identified as the only manufacturer approved by the Food and Drug Administration to produce and distribute Tamiflu capsules in the United States. The department therefore determined a limited competition procurement is justified due to Roche being the only responsible source and reasonable price based on prior contract pricing for the same supplies.